Anhui Kedgene Biotechnology

Main focus: Next generation T cell based therapies

Company stage: Clinical

Diseases: Solid tumors

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Anhui, China

Website: https://www.ankebio.com/english/index.php

Anhui Kedgene Biotechnology develops next generation T cell based therapies for solid tumor treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimize efficiacy and safety.

Tags

HashtagAnhui Kedgene Biotechnology Co.,Ltd

close
Search CRISPR Medicine